%0 Journal Article
%A Stintzing, Sebastian
%A Klein-Scory, Susanne
%A Fischer von Weikersthal, Ludwig
%A Fuchs, Martin
%A Kaiser, Florian
%A Heinrich, Kathrin
%A Modest, Dominik Paul
%A Hofheinz, Ralf-Dieter
%A Decker, Thomas
%A Gerger, Armin
%A Angermeier, Stefan
%A Rumpold, Holger
%A Dickhut, Andreas
%A Öhler, Leopold
%A Gruenberger, Birgit
%A Niedersuess-Beke, Dora
%A Sandmann, Matthias
%A Winder, Thomas
%A Trojan, Joerg
%A Prager, Gerald
%A Held, Swantje
%A Kumbrink, Jörg
%A Schmiegel, Wolff
%A Baraniskin, Alexander
%A Heinemann, Volker
%T Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.
%J Journal of clinical oncology
%V 43
%N 12
%@ 0732-183X
%C Alexandria, Va.
%I American Society of Clinical Oncology
%M DKFZ-2025-00290
%P 1463-1473
%D 2025
%Z 2025 Apr 20;43(12):1463-1473
%X The FIRE-4 study randomly assigned patients with first-line RAS wild-type (RASwt) metastatic colorectal cancer to either flourouracil (FU), folinic acid, and irinotecan (FOLFIRI) plus cetuximab until progression or intolerable toxicity (standard arm) or to FOLFIRI plus cetuximab followed by a switch maintenance treatment using FU plus bevacizumab (experimental arm). Here, we investigate the relevance of liquid biopsy (LB) RAS and BRAF testing compared with tissue-based analyses.LBs were taken at baseline and during treatment and were analyzed for RAS and BRAFV600E mutations using the in vitro diagnostics-certified ONCOBEAM RAS procedure (Sysmex Inostics) and digital-droplet polymerase chain reaction technology.Six hundred seventy-two RASwt patients were randomly assigned. LBs of 540 patients were evaluable at baseline. Of those, 70 (13
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39903881
%R 10.1200/JCO.24.01174
%U https://inrepo02.dkfz.de/record/298573